References
- Trinchieri G., Matsumoto-Kobayashi M., Clark S. G., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med 1984; 160: 1147–1169
- Greene W. C. The human interleukin 2 receptor: a molecular and biochemical analysis of structure and function. Clin. Res. 1987; 35: 439–450
- Wagner D. K., Kiwanuka J., Edwards B. K., Rubin L. A., Nelson D. L., Magrath I. T. Soluble interleukin 2 receptor levels in patients with undifTerentiated and lympho-blastic lymphomas: correlation with survival. J. Clin. Oncol. 1987; 5: 1262–1274
- Pizzolo G., Chilosi M., Vinante F., et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. B. J. Cancer 1987; 55: 427–428
- Hellman S., JafTe E. S., Devita V. T. Hodgkin's Disease. Cancer: Principles and Practice of Oncology, V. T. Devita, S. Hellman, S. A. Rosenberg. J. B. Lippincot, Philadelphia 1989; 1696–1740
- Devita V. T., Jaffe E. S., Mauch P., Longo D. L. Lymphocytic Lymphomas. Cancer: Principles and Practice of Oncology, V. T. Devita, S. Hellman, S. A. Rosenberg. J. B. Lippincot, Philadelphia 1989; 1741–1798
- Fanslow W. C., Clifford K. N., Park L. S., et al. Regulation of alloreactivity in vivo by IL4 and the soluble IL4 receptor. J. Immunol. 1991; 147: 535–540
- Kawakami Y., Custer M. C., Rosenberg S. A., Lotze M. T. IL4 regulated IL2 induction of lymphokine-activated killer cell activity from human lymphocytes. J. Immunol. 1989; 142: 3452–3461
- Spits H., Yssel H., Paliard X., Kastelein R., Figdor C., De Vries J. E. IL4 inhibits IL2 mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed lymphocyte cultures. J. Immunol. 1988; 141: 29–36
- Paul W. E. Interleukin 4: a prototypic immuno-regulatory lymphokine. Blood 1991; 77: 1859–1870
- Kendall M. G. Rank Correlation Methods, 4th edn. Griffin, London 1970
- Lim S. H., Worman C., Jewell A., Tsakona C., Giles F. J., Goldstone A. Lymphocyte activation and serine esterase induction following recombinant interleukin 2 infusion for lymphoma and acute leukaemias. Cancer Immunol. Immunother. 1991; 33: 133–137
- Voss S. D., Hank J. A., Nobis C. A., Fisch P., Sosman J. A., Sondel P. M. Serum levels of the low-affinity interleukin 2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol. Immunother. 1989; 29: 261–269